Targacept to Present at the 15th Annual BIO CEO & Investor Conference BIO CEO & Investor Conference 2013 Business Wire WINSTON-SALEM, N.C. -- February 4, 2013 Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that Dr. Stephen A. Hill, President and ChiefExecutive Officer, is scheduled to present at the 15th Annual BIO CEO & Investor Conference at The Waldorf Astoria New York in New York City on Monday, February 11, 2013 at 1:00 p.m. Eastern Time. The presentation will be webcast and accessible from the Investor Relations page of Targacept’s website, www.targacept.com. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will be available for replay on the Investor Calendar section of the Investor Relations page of Targacept’s website for at least two weeks following the event. About Targacept Targacept is developing a diverse pipeline of innovative NNR Therapeutics(TM) for difficult-to-treat diseases and disorders of the nervous system. NNR Therapeutics selectively modulate the activity of specific neuronal nicotinic receptors, unique proteins that regulate vital biological functions that are impaired in various disease states. Targacept’s clinical pipeline includes multiple Phase 2 product candidates, all representing first-in-class opportunities. Targacept leverages its scientific leadership diverse pipeline to attract significant collaborations with global pharmaceutical companies. For more information, please visit www.targacept.com. TARGACEPT Building Health, Restoring Independence^® Contact: Targacept, Inc. Alan Musso, 336-480-2186 SVP, Finance and Administration and CFO email@example.com or Linnden Communications Michelle Linn, 508-362-3087 firstname.lastname@example.org
Targacept to Present at the 15th Annual BIO CEO & Investor Conference
Press spacebar to pause and continue. Press esc to stop.